Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly
used for the treatment of a wide variety of retinal diseases, including age-related macular …

The treatment of ocular neovascular diseases is being revolutionized by intravitreal
therapies targeting vascular endothelial growth factor (VEGF). Two agents are approved for …

Ocular ischemic syndrome is a rare condition, which is caused by ocular hypoperfusion due
to stenosis or occlusion of the common or internal carotid arteries. Atherosclerosis is the …

Anti-vascular endothelial growth factor (anti-VEGF) therapy has been shown to be effective
at improving vision in patients with macular oedema due to diabetic retinopathy and vein …

Purpose To investigate changes in the area of the foveal avascular zone (FAZ) in patients
with retinal vascular disease. Patients and methods This retrospective, consecutive study …

Purpose.: Preretinal fibrovascular membranes (FVMs) form as a sequela to proliferative
diabetic retinopathy (PDR), and their presence can lead to a severe decrease of vision. The …

Background We have previously shown that bevacizumab, but not ranibizumab, is taken up
by porcine RPE cells. In this study, the effects of bevacizumab and ranibizumab on …

Background This study evaluated the effect of intravitreal injection of bevacizumab (IVB) on
macular edema associated with diabetic retinopathy (DME) or branch retinal vein occlusion …

Background Bevacizumab, a humanized monoclonal antibody against vascular endothelial
growth factor (VEGF), has been reported to cause rapid regression of anterior segment …

Aim To record ocular vascular events following injections of vascular endothelium growth
factor (VEGF) antagonists. Methods Collaborative multicenter case series (48 cases) …